Keeping Track: US FDA Receives Submissions Galore As Year Ends

A roundup of new applications submitted to FDA’s Center for Drug Evaluation and Research.

Keeping Track Feature image

The last weeks of 2018 saw a flurry of submissions to the US FDA’s Center for Drug Evaluation and Research, including at least four novel agents. Indeed, had the partial government shutdown not precluded further submissions, the end of the year might have turned into a downright blizzard.

AbbVie Inc.’s upadacitinib could become the third oral rheumatoid arthritis therapy targeting Janus kinase (JAK), joining Pfizer Inc.’s...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet